#USA #Azitra #ATR-12 #Branford #NYSE American

Azitra Faces NYSE American Non-Compliance Notice

Azitra, Inc., a clinical-stage biopharmaceutical enterprise focusing on precision dermatology treatments, recently announced it has received a notification regarding non-compliance from NYSE American. This notice came from the staff of the Exchange, indicating that Azitra did not meet the required continued listing standards as stipulated under Section 1003(a)(iii) of the NYSE American Company Guide.

The Company Guide necessitates that companies listed on NYSE American maintain stockholders' equity of at least $6 million if they have reported losses in their continuing operations or net losses over the past five fiscal years. Notably, this isn’t the first compliance concern for Azitra; in October 2025, they were also alerted about falling short of the minimum stockholders' equity requirement of $4 million under Section 1003(a)(ii) due to losses reported in three of the past four fiscal years.

In response to these notifications, Azitra submitted a compliance plan to NYSE American on October 31, 2025. The plan outlines the steps they intend to take to meet the requirements under Section 1003(a)(ii) by April 1, 2027, which was subsequently accepted by the Exchange on December 16, 2025. Under the terms of this notice, Azitra has until April 1, 2027, to restore compliance or face potential delisting proceedings if their efforts remain inadequate.

Despite the serious nature of this notice, it does not have an immediate effect on Azitra’s common stock trading or listing status. The Company remains dedicated to exploring various funding solutions to ensure that it adheres to the regulatory requirements set forth by the NYSE American. Moreover, Azitra's ongoing operations will not be affected, and they maintain adherence to the reporting mandates as designated by the U.S. Securities and Exchange Commission (SEC).

Furthermore, Azitra disclosed that its Annual Report for the fiscal year that ended on December 31, 2025, included an auditor's opinion with a substantial doubt concerning the Company's ability to continue as a going concern. The company believes it can overcome current challenges through strategic funding initiatives and compliance with Exchange requirements.

About Azitra, Inc.
Azitra is at the forefront of precision dermatology, with its lead program ATR-12 targeting Netherton syndrome, a serious chronic skin condition that currently lacks treatment options. This program is undergoing a Phase 1b clinical trial aimed at adult patients affected by this condition. In addition to ATR-12, Azitra is developing ATR-04, which addresses skin rashes associated with EGFR inhibitors and has received Fast Track designation from the FDA, affecting around 150,000 patients in the U.S. Their innovative approach utilizes a microbial library and advanced technologies such as artificial intelligence and machine learning to analyze and predict treatment outcomes effectively.

In light of its current status, Azitra’s management is committed to ensuring that they meet the necessary standards outlined by NYSE American and continues to provide investors with updates on their progress. The coming months are critical for the firm as it navigates the challenges ahead and strives to secure a stable financial future and compliance with regulatory standards.